Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease

Marie Courbebaisse, Hind Mehel, Camille Petit-Hoang, Jean-Antoine Ribeil, Laurent Sabbah, Véronique Tuloup-Minguez, David Bergerat, Jean-Benoit Arlet, Aurélie Stanislas, Jean-Claude Souberbielle, Hervé Le Clésiau, Rodolphe Fischmeister, Gérard Friedlander, and Dominique Prié

Disclosures: Dominique Prié has received honoraria for lectures from Amgen, Shire and Viforpharma, during the past 2 years. Marie Courbebaisse declares fees from Amgen, Merck-Serono and Roche. Jean-Antoine Ribeil has received fees from AddMedica, Bluebirdbio, Novartis, Solbi and Vitalaire Jean-Claude Souberbielle received lecture or consulting fees from Diasorin, Ipsen, MSD, Roche Diagnostics and Rottapharm. Jean-Benoit Arlet declares lecture fees from Addmedica and Novartis Hind Mehel, Laurent Sabbah, Véronique Tuloup-Minguez, David Bergerat, Aurélie Stanislas, Hervé Leclésiaux, Rodolphe Fischmeister, Gérard Friedlander: have nothing to declare

Contributions: All the authors contributed to this work as follows: Marie Courbebaisse, Jean-Antoine Ribeil, Jean-Benoit Arlet, and Aurélie Stanislas participated to the recruitment and the clinical investigation of the patients. Hind Mehel, Véronique Tuloup-Minguez, David Bergerat and Rodolphe Fischmeister performed the in vitro experiments. Laurent Sabbah performed the echocardiography. Jean-Claude Souberbielle performed the biochemical measurements Hervé Leclésiaux recruited the healthy volunteers of the control group. Gérard, Friedlander participated to the presentation and the discussion of the results. Dominique Prié designed the study, performed the FGF23 measurements, organized the clinical investigation of the patients, supervised the in vitro experiments, performed the analysis of the data and wrote the manuscript.